PROCEPT BioRobotics (NASDAQ:PRCT) reported second-quarter revenue growth of 19% year over year while lowering its full-year U.S. procedure outlook, citing softer activity at legacy AquaBeam accounts. The company now expects 2026 U.S. procedures of 54,000 to 56,000, representing growth of approximately 25% to 29% from 2025. U.S. system revenue increased 32% year over year to $29.1 million. The company expects new U.S. system average selling prices of approximately $480,000 to $490,000 in the second half. About PROCEPT BioRobotics (NASDAQ:PRCT)PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH).